{"title": "Find a Doctor", "author": null, "url": "https://www.dana-farber.org/find-a-doctor/kenneth-c-anderson/", "hostname": "dana-farber.org", "description": "Kenneth C. Anderson, MD - Medical Oncology. Dr. Anderson graduated from Johns Hopkins Medical School, trained in internal medicine at Johns Hopkins Hospital, and completed hematology, medical oncology, and tumor immunology training at Dana-Farber Cancer Institute. He serves as chief of the Division of Hematologic Neoplasia, director of the ...", "sitename": "Kenneth C. Anderson, MD - Dana-Farber Cancer Institute", "date": "2013-02-20", "cleaned_text": "cells promotes the development of multiple myeloma with extramedullary disease. Leukemia. 2023 Sep; 37(9):1952. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37464071) A pandemic preparedness network for individuals living with compromised immune systems. Blood Adv. 2023 08 08; 7(15):3925-3927. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37023227) Determinants of response and resistance to T cell-engaging therapies in multiple myeloma. Nat a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma. Clin Cancer Res. 2023 Jul 18. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37463058) Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs. Clin Exp Med. 2023 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36877894) Ubiquitin receptor PSMD4/Rpn10 is a target Blood. 2023 05 25; 141(21):2599-2614. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36630605) UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease. Leukemia. 29(9):1807-1821. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36780189) Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. Semin View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/37173155) Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. 2023 07 15; 129(14):2179-2191. View in: myeloma. Blood. 2023 04 141(14):1724-1736. (JNK) in: Heterogeneity of patients with and active myeloma. synthetase as a novel therapeutic target in multiple myeloma. Blood Cancer J. 2023 Feb 07; 13(1):24. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36746923) Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics. Blood Cancer J. 2023 02 03; 13(1):23. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36737429) A MIR17HG-derived long noncoding RNA an essential chromatin scaffold for protein interaction and myeloma growth. 26; 141(4):391-405. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36126301) Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma. Blood Cancer J. 2023 01 12; 13(1):12. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36631435) Improving NK cell function with NKTR-255, a novel polymer-conjugated human 7(1):9-19. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35882498) and adaptive immune tumor microenvironment Waldenstr\u00f6m macroglobulinemia. Int J Cancer. 2023 05 01; 152(9):1947-1963. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36533670) In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors. Blood Cancer J. 2022 12 20; 12(12):171. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36535935) Author Correction: Functional dissection of non-coding variation multiple myeloma Nat in: Front Oncol. 2022; 12:1032775. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36330495) The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 09 15; 140(11):1229-1253. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35653592) Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma. 2022 09 13; antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer J. 2022 08 16; 12(8):118. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35973981) Promises and Challenges Cells. 2022 08 14; 11(16). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/36010596) Perspectives Discov. 2022 07 06; 3(4):273-284. View for the SRC family kinase HCK as a driver of until Progression in Myeloma. N Engl J Med. 2022 07 14; as an immunotherapy target Cancer Res. as an immunotherapeutic target in multiple 2022 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35344764) Quality of life, psychological distress, and prognostic perceptions in patients with multiple refractory multiple myeloma (ICARIA-MM): follow-up analysis of 2022 03; 23(3):416-427. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35151415) Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment. Front Oncol. 2022; 12:820768. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35211412) Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022 Feb; depend DDI2/NRF1-mediated proteasome response for in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34653241) Cell-free DNA the detection of emerging treatment in relapsed/ refractory multiple myeloma. Leukemia. 2022 dissection multiple Nat Commun. a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology. Blood 2021 12 14; 5(23):5429-5438. View in: Antigens the New Frontier of Targeted Immunotherapy in Multiple Myeloma. Cancers (Basel). 2021 Dec in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34885245) IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. of histone modifiers in multiple myeloma: clinical applications. Blood 2021 Oct; 40(41):6057. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34489552) Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clin Cancer Res. 2021 10 Multiple Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent 12(17):1736. View immunosuppression myeloma. Leukemia. 2022 01; 36(1):138-154. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34290359) Discov. 2021 Jul; 2(4):289-290. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/35015678) 2(4):289-290. View in: Survival of Multiple Myeloma within the Bone Marrow Microenvironment. Blood Cancer signaling 2(4):370-387. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34258103) miR-15a/16-1 deletion in B cells promotes plasma cell and mature B-cell neoplasms. Blood. 2021 04 08; 137(14):1905-1919. 2021 review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment Br J Haematol. 2021 08; 194(3):496-507. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33724461) Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare. Blood Cancer Discov. 2021 03; 2(2):119-124. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/34179821) Treatment of refractory multiple myeloma: recommendations from the International Myeloma Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 02 08; 12(1):868. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33558511) Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. Front Oncol. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33487632) Identification novel target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13. Cancer J. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33441535) Signaling Pathway Mediating (Basel). 2021 Jan 08; 13(2). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33435632) Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020 12 24; 136(26):3033-3040. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33367546) Melflufen establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020 MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury. Cancer Res. 2021 02 01; 81(3):713-723. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33288657) The JAK-STAT pathway CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood. 2020 11 12; 136(20):2334-2345. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32844992) Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset. Blood. 2020 Nov 06. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33156904) VIS832, a novel CD138-targeting monoclonal antibody, induces of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. Blood Cancer J. 2020 11 02; 10(11):110. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33149123) Novel prognostic scoring system for hematopoietic cell in multiple 11; 191(3):442-452. View View Discov. newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. Med. 9(23):8923-8930. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33049118) Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020 10 01; 105(10):2358-2367. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/33054076) Revealing the impact of structural in multiple Blood Cancer Discov. the potency of AMG 701 in multiple myeloma preclinical models. dexamethasone in overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020 09 04; 10(9):91. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32887873) Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, View Isatuximab Acts Independent, Myeloma in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32922390) Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020 Jul 23. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32703792) YWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32187357) Genome-Wide Somatic Alterations in Reveal a Outcome Group. J Clin Oncol. 2020 09 20; of CD8+ anti-BCMA mRNA CAR T for treatment against 34(7):1971. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31949267) Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32533060) IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients. Eur J Haematol. 2020 Sep; 105(3):326-334. View BCMA-Targeting New Era of Immunotherapy in Multiple Myeloma. Cancers (Basel). 2020 Jun 05; 12(6). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32516895) Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center in China. of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389. 2021 02; View 04 21; 11(1):1917. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32317634) Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a. Mol Cancer Res. Allogeneic 26(8):1414-1424. placebo-controlled, perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma 03 24; 10(1):5324. 34(3). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32212133) Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. Cancer Res. 2020 05 15; 80(10):2031-2044. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32193289) The safety of current and emerging therapies for multiple myeloma. Expert Opin Drug Saf. 2020 Mar; 19(3):269-279. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32098519) Proteomics-inspired precision medicine for treating and understanding multiple myeloma. Expert Rev Precis Med Drug Dev. 2020; 03; 39(13):2786-2796. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/32024967) A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Adv. 2020 01 14; 4(1):181-190. View in: myeloma (ICARIA-MM): a randomised, multicentre, open-label, 12 07; in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31735560) Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple Adv. 2019 11 12; 3(21):3248-3260. View Trial Anti-CXCR4 Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Res. 2020 01 15; 26(2):344-353. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31672767) The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Adv. 2019 10 08; 3(19):2895-2904. View plerixafor combination with bortezomib as a chemosensitization relapsed/refractory multiple 2020 02; 34(2):567-577. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31462737) Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. against 34(1):210-223. plasmacytoid dendritic cells triggers anti-myeloma immunity. 2019 08 12; 9(8):64. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31406111) Humanistic and 2019 Aug B cell View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31277554) Insights MicroRNA deregulation on pre-RNA processing network in multiple myeloma. Leukemia. 2020 01; 34(1):167-179. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31182781) International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/31162104) the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes myeloma previously treated with lenalidomide (OPTIMISMM): a Antitumor Res. 2019 May 01; 25(9):2938. View in: Development and covalent Rpn13 of copy Cancer J. 2019 03 26; 9(4):39. View 2019 07 134(2):123-133. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30862646) Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in 2019 in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. Am J Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis. Cancers (Basel). 2019 01 09; 11(1). View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30634515) Contribution of Inhibition View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30590042) BCMA CAR T-cell therapy arrives 2018 Dec; 30; 9(94):36646-36647. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30613345) Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist. Am 2018(1):88-96. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30504296) Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist. Hematology Am Soc Program. 2018 of Proteomics. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30401751) Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018 11 09; 8(11):109. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30413684) Preclinical assessment of an targets BCMA on multiple myeloma I/II A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2019 01 15; 25(2):478-486. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30279233) Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 12 06; 132(23):2456-2464. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30249784) Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenstr\u00f6m Macroglobulinemia. Clin 25(1):369-377. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30206161) Genomic patterns of progression Commun. 2018 08 22; 9(1):3363. View in: biological significance of histone modifiers in multiple myeloma: clinical applications. Blood Cancer J. 2018 08 22; 8(9):83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30190472) APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: implications. Leukemia. 2019 02; 33(2):426-438. View in: Noncleavable Linked Maytansinoid 2018 12 15; 24(24):6570-6582. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30131388) Targeting B Cell Maturation Antigen (BCMA) in Multiple Potential Uses Ligand 1. Front Immunol. 2018; 9:1822. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30147691) The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia. 2019 01; 33(1):171-180. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/30026574) A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019 01; 33(1):159-170. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29967379) Promise of Immune Pract. 2018 07; 14(7):411-413. View mutational drivers reveals oncogene dependencies in multiple myeloma. 09; in patients with multiple myeloma: phase 2 study. Br J Haematol. 2018 08; 182(4):495-503. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29808907) Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018 12; 32(12):2604-2616. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29789651) Meaningful changes in Haematologica. 2018 08; 103(8):1380-1389. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29748440) Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. Br J Haematol. 2018 05; 181(4):433-446. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29748955) phase lenalidomide, bortezomib and dexamethasone in transplant-ineligible intergenic non-coding have an independent impact on survival in myeloma. Leukemia. 2018 12; 32(12):2626-2635. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29749396) Res. 2018 05 15; 78(10):2747-2759. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29559475) Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. J cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018 09; View The [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29359239) Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. Clin implications and View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29268619) View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29196868) in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. 2017 Dec; With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. J Oncol Pract. 2018 02; 14(2):129-133. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29182492) Platelet Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018 01 20; 36(3):283-299. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29182495) Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018 01 18; 131(3):301-310. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/29150421) Monoclonal Antibody: A New 2017 Nov 14; 6(4). View in: arsenic compounds induce in vitro and in vivo activity against multiple myeloma. assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of 8(46):80109-80123. and post-hoc analyses View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28708596) Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28643330) Overcoming multiple era 2017 Jun 08. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28621266) A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple a Therapeutic Target in Multiple Myeloma. Clin Cancer Res. 2017 Sep 01; 23(17):5225-5237. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28442502) The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clin Cancer 06; 376(14):1311-1320. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28379796) The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017 04 04; 19(1):218-224. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28380360) Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017 04; 18(4):e206-e217. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28368259) Should minimal residual disease negativity be the end point of myeloma therapy? Blood Adv. Repair and Triggers Apoptosis in Myeloma Cells. Clin Cancer CD38 Suppresses and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. Clin Cancer Res. cytotoxic role of p21-activated kinase 4 in multiple in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28096095) p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 03 09; 129(10):1308-1319. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28082445) Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, 4:90. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28018601) A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016 Nov 22; 7(47):77326-77341. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27764795) Progress and Paradigms in Multiple Cancer Res. 2016 Nov 15; 22(22):5419-5427. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/28151709) Immune Therapies in Multiple Res. 2016 Nov 15; Acad View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27799547) AACR Cancer Progress Report 2016: Improving Lives Through Research. Clin Cancer Res. 2016 10 01; 22(19):4759. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27697990) A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. in suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. J Exp Med. 2016 08 22; 213(9):1705-22. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27455953) A new era of immune therapy in multiple myeloma. Blood. 2016 07 21; 128(3):318-9. View immune suppressive 128(12):1590-603. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27418644) Transcriptome sequencing macroglobulinemia. Blood. 2016 08 [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27301862) Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Dual NAMPT Synergistic Waldenstr\u00f6m Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Cancer Res. 2016 Dec 15; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27287071) A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. Blood. 2016 07 14; 128(2):249-52. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27207793) Therapeutic Targeting hyperactivation multiple myeloma and solid tumour patients. 2016 Sep; View promote human multiple myeloma growth and immunosuppression in the bone marrow inhibitors bench Int J Hematol. 2016 DNA and cytotoxicity in multiple Mol Cancer Ther. 2016 Mar 28. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27022108) Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27009059) Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clin Cancer Res. 2016 Aug 15; 22(16):4206-4214. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27006493) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016 06 16; of Vorinostat (MK-0683) in Combination With Bortezomib [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26907633) Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma. Br Haematol. 2016 Apr; 173(1):82-8. View in: KDM3A-KLF2-IRF4 2016 Jan 05; 7:10258. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26728187) Vision Statement for Multiple Myeloma: Directions. Cancer Treat Res. 2016; 169:15-22. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/27696255) Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma Blood. 2016 Mar 03; 127(9):1138-50. View Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study. Clin Cancer Res. 2016 Mar 15; 22(6):1378-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26644410) Combination of a Selective a Signaling Pathway Inhibitor combination lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 13 Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Cancer Res. 2016 View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26527748) Multiple Myeloma, [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26456076) AACR Cancer Progress Report 2015: Transforming Lives Through Precision Medicine. Clin Cancer Res. 2015 Oct 01; 21(19):4247. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26429978) American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2039-2051. View in Cancer Res. 2015 Oct 15; 75(20):4384-4397. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26249174) Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10; 33(26):2863-9. Aug; 43(8):732-41. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26118499) Synthetic Approaches Exploiting DNA Damage in Aggressive Cancer Discov. 2015 Sep; 5(9):972-87. View or Myeloma. J Med. 2015 View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26035255) Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26032514) Promising therapies 126(3):300-10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26031917) The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/26005854) Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25979485) Multiple myeloma: new uses for available agents, excitement for the future. J Natl Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors. J Leuk (Los Angel). 2015 Jun; 3(2). View in: clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015 Jun; 169(6):851-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25833301) CCR In the beginning, there was PS-341. Clin Cancer Res. 2015 Mar 01; 21(5):939-41. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25733705) Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol. 2015 Apr; 90(4):314-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25557740) The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. May 01; View in: assessment predicts in elderly myeloma patients: an International Myeloma Working Blood. 2015 03 26; 125(13):2068-74. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25628469) Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015 11(8):1153-68. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25832873) Clinical Cancer Cancer Res. 2015 Jan 01; 21(1):3. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25564568) Targeting the bone T lymphocytes against breast cancer, colon cancer, pancreatic cancer cells. Oncoimmunology. 2014; 3(12):e970914. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25941601) Current treatment landscape multiple Rev Clin Oncol. 2015 Jan; 12(1):42-54. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25421279) Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology Am Soc View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25696864) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov; 15(12):e538-48. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25439696) Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease. BMC effectively myeloma cells and demonstrate enhanced efficacy in vivo. J Control Release. 2014 Dec 28; 196:113-21. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25212892) Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140035. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25984343) Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014 Nov-Dec; 64(6):422-44. View in: 100(1):100-6. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25261096) Differential and limited expression of mutant alleles in multiple myeloma. Blood. 2014 Nov 13; 124(20):3110-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25237203) AACR cancer progress report 2014: transforming lives through research. Clin Cancer Res. 2014 Oct 01; 20(19):4977. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25228533) Pyk2 promotes tumor progression 124(17):2675-86. View View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25172964) the treatment of multiple myeloma. Hematol Oncol Clin North Am. The challenge of cross-trial data. Haematologica. 2014 Aug; 99(8):e145-6. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25082787) Treatment macroglobulinemia (WM) related disorders: 124(9):1404-11. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25027391) Looking forward: an update to the CCR instructions for authors. Clin Cancer Res. 2014 Jul 15; 20(14):3629. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25028504) Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24958808) Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res. 2014 Aug 15; 74(16):4458-69. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24934808) Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Advisory Oct; 14(5):356-69. treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol. 2014 Jun; 20(6):599-606. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24813251) Multiple myeloma: advances reported in 2013 are useful in the clinic. J Natl patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J mass spectrometry approach for global metabolomic profiling and case study on drug-resistant multiple myeloma. 2014 Apr 01; 86(7):3667-75. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24622324) miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/\u00df-catenin/BCL9 pathway. Cancer Res. 2014 Mar 15; Novel anti-B-cell maturation (GSK2857916) selectively killing of May 15; 123(20):3128-38. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24569262) Daratumumab 23(4):445-52. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24555809) with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. with induces cytotoxicity breast cancer cells. Int J Oncol. 2014 Apr; 44(4):1171-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24481412) A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and Blood. 2014 Mar 06; 123(10):1461-9. View in: to M. Feb 10; 32(5):478. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24419117) International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. in dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20; 123(12):1826-32. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24421329) The heavy chain Commun. 2014; 5:2997. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24429703) Future agents and treatment in multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):127-41. View in: of significantly reduces myeloma sensitivity to single-agent therapy. Blood. 2014 Jan 30; 123(5):632-9. View UCHL5 induces apoptosis in resistance. Blood. 2014 Jan 30; 123(5):706-16. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24319254) Announcing the AACR Cancer Progress Report 2013. Clin Cancer Res. 2013 Oct 15; 19(20):5545. View drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell via c-Jun Lett. 2014 Feb 28; 343(2):286-94. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24120758) Clinical translation in multiple in: and the genetics of multiple myeloma to identify new therapeutic targets. Semin Oncol. 2013 Oct; 40(5):537-48. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24135398) Phase transitions IgG 2013 Sep 28; 139(12):121904. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24089716) Vorinostat or placebo in combination with bortezomib in with multiple myeloma (VANTAGE 088): AACR Cancer 15; 19(20 Suppl):S4-98. Phase Ib study bortezomib in or relapsed and refractory multiple Oncol. 2013 T lymphocyte epitopes derived from HLA-DO\u00df as a novel target for multiple myeloma. Br J Haematol. 2013 Nov; 163(3):343-51. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/24032635) Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant. 2013 Nov; IgD and IgE 2013 in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase 15; 122(7):1243-55. View in: Minimal residual disease autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer through inhibition of NF Kappa B pathway and proteasome Br J Haematol. 2013 Jul; 162(2):210-20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23647456) Therapeutic bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol. 2013 of novel alkylating agent, melphalan-flufenamide, against myeloma cells. Jun 01; 19(11):3019-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23584492) Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013 Jul; 37(7):829-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23582718) View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23454749) Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration. Biol Blood Marrow Transplant. 2013 Jun; 19(6):858-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23545332) New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013 Jul 01; 19(13):3337-44. View in: Histone deacetylase inhibitors in 2013 Mar; 9(3):410-2. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23221771) inhibits vitro and in vivo multiple myeloma cell growth. Clin Cancer Res. 2013 Apr 19(8):2096-106. View in: View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23372151) In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14; 121(11):2051-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23321251) humans. Blood. 2013 Apr 11; 121(15):2975-87. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23321256) Salvage second hematopoietic cell Marrow Transplant. 2013 May; 19(5):760-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23298856) Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013 Feb 01; 190(3):1360-71. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23293352) Results of of the deacetylase inhibitor panobinostat 21; 121(8):1296-303. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23287861) New insights into the 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and Mar 121(11):1961-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23243282) Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23240658) Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. Clin 2013 Feb in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop. and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood. 2012 Dec 13; 120(25):4929-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/23074271) Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer analysis of \u00df-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. MLN9708/2238 08; 120(19):3958-67. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22983447) Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. Br J Haematol. 2012 Nov; 159(3):340-51. induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11; 22(3):345-58. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22975377) Gauging progress in a decades-old Cancer 2012 Nov 01; 18(21):5833. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22977189) Targeting NAD+ salvage pathway 2012 Aug 14; 109(33):13359-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22847421) How I treat plasma cell Blood. 2012 20; 120(12):2376-89. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22837533) Canonical 13; antitumor 2012 Sep 01; 18(17):4669-81. View in: Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res. 2012 Sep 01; 18(17):4850-60. View Hematol. 2012 Jul; 49(3):223-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22726545) Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target? J extramedullary, relapsed, and refractory multiple myeloma involving the liver across with cyclophosphamide, inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012 Aug and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol. 2012 Aug; 158(4):472-80. in: 10; , the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and activity. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22533610) inhibits multiple growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br J Haematol. 2012 Jun; 157(6):718-31. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22533681) Blockade of XBP1 splicing by inhibition of IRE1a is a promising therapeutic option in multiple myeloma. Blood. 2012 Jun and synergistic multiple myeloma targets discovered through systematic combination screening. Mol Cancer Ther. 2012 Jul; 11(7):1432-42. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22474168) The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9. II the inhibitor panobinostat single View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22288662) Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012 Feb 21; 9(3):135-43. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22349016) Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8. View in: the AACR Clinical and Translational Cancer Research Think Tank meeting. Clin Cancer Res. 2012 Feb 01; 18(3):607-11. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22298892) Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 2012 Apr 12; 119(15):e131-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22289890) Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22267603) Preclinical activity, a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in 2012 Mar 15; 119(11):2579-89. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22262760) Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented Blood. 2012 Mar 01; 119(9):2074-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22246035) David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple Oncol. 2012 Feb 01; 30(4):445-52. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21991938) The future for patients with relapsed/refractory multiple myeloma. Oncology (Williston [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/25188476) Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol the therapeutics, adaptor molecule p130Cas. correlates Nov 25; 334(6059):1129-33. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22033517) with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer. Immunotherapy. novel modulator SRT1720 multiple myeloma inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol. 2011 lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol. 2011 Nov; 155(3):349-61. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21902685) BET bromodomain inhibition as a strategy to c-Myc. Cell. 2011 Sep 16; 146(6):904-17. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21889194) Novel therapies in MM: from the aspect of preclinical studies. Int J Hematol. 2011 Oct; 94(4):344-354. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21881879) sp1 multiple Cancer Res. 2011 Oct 15; 17(20):6500-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21856768) A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and J Haematol. 2011 Sep; 154(6):745-54. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21777223) Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62. View myeloma: One. 2011; 6(7):e20226. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21750699) In vitro and in vivo activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma 15; 17(16):5311-21. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21724551) Anti-tumor activity and phenethyl MGUS 2011 Jun; 25(7):594, 596. phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. J Hematol. 2011 Jul; 86(7):573-8. multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood. 2011 Jul 21; 118(3):535-43. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21596852) Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol. 2011 Jun; 153(6):729-40. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21534941) Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 2011 May and inhibits May 26; 117(21):5692-700. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21454451) International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011 Jun 09; 117(23):6063-73. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21447828) Initial genome sequencing Mar Aurora kinase and either alone or in combination with lenalidomide. Clin Res. 2011 May 15; 17(10):3259-71. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21430070) Hematology: Setting the standard for multiple Clin Oncol. in marrow Cancer Res. 2011 Mar 15; 17(6):1225-33. View Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. Br J Haematol. 2011 Apr; 153(2):212-21. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21375521) Res. 2011; 2011:924058. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/22046572) A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics. 2011 Apr; 11(8):1391-402. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21365752) Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011 Apr 28; 117(17):4409-19. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21321360) Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011 May 05; 117(18):4696-700. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21292777) Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011 May 05; 117(18):4701-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21292778) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 05; in management of diagnosed multiple myeloma. Expert Rev Hematol. 2011 Feb; 4(1):51-60. View cyclin-dependent kinase inhibition in myeloma: biological and 2011 Feb; 152(4):420-32. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21223249) Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011 Feb; 152(4):367-79. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21219297) New insights for tracking multiple myeloma engraftment, growth, and response to therapy. J Biomed Opt. 2011 Jan-Feb; 16(1):011006. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21280893) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011 Feb 01; 186(3):1840-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21187443) Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol. 2011 Jan; 152(2):155-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21114484) Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol. 2011 Jan; 86(1):1-15. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20942854) Multiple myeloma: biology the Rev. 2010 Nov; 24 Suppl 1:S5-11. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21126636) Vaccination with fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Jan 13; 117(2):393-402. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21030562) MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood. 2010 Oct 20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20962322) Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010 Nov 20; 28(33):4976-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20956629) Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma. 2010 Oct; 51(10):1779-92. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20795787) Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstr\u00f6m Am J Hematol. 2010 Sep; novel orally active proteasome ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 02; [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20805366) What can CCR Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 Oct 28; 116(17):3227-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20651070) bortezomib: monotherapy multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol. 2010 Aug; Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20694078) Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Jun 15; 16(12):3260-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20530693) PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010 Sep 02; 116(9):1460-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20505158) Kidney disease associated with plasma Sep 02; 116(9):1397-404. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20462963) Monoclonal of Haematol. 2010 Jul; 150(1):28-38. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20507313) The treatment of myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21415962) A therapeutic role for targeting pathways. Cycle. 2010 May; 9(9):1722-8. View Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20395418) Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 115(25):5202-13. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20382844) to identify stroma-induced changes to anticancer drug Nat Med. 2010 Apr; 16(4):483-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20228816) Pharmacodynamic (marizomib) in a the bone marrow microenvironment in multiple myeloma cells. Blood. 2010 May 06; 115(18):3772-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20228272) Blockade of the MEK/ERK signalling AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and 2010 May; A promotes myeloma-induced osteolysis and is promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5124-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20194748) Tailoring treatment for multiple myeloma patients with relapsed disease. in: The evolution and of therapy in multiple myeloma. Med Oncol. 2010 Jun; 27 Suppl 1:S1-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20169425) Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and Waldenstrom in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20142586) Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20142598) Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; 201-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20118399) Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20110419) Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's activity vitro and inhibits tumour angiogenesis in a multiple myeloma model acute lymphoblastic leukemia. Proc Natl Acad View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20018760) The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 2010 Apr 08; 115(14):2827-34. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19965618) Interactions of the Hdm2/p53 may enhance the antitumor activity of 2009 Dec high-affinity fully for the treatment of multiple myeloma. Res. 2009 Dec 01; of novel proteasome vitro and in cytotoxicity in [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19930971) From the guest editor: the evolving treatment paradigm in multiple myeloma. Cancer J. 2009 Nov-Dec; 15(6):456. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/20010163) of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. 2009 Oct 06; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19800576) relapsed and View vitro anti-myeloma by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Oct 01; 69(19):7577-86. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19738061) High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15; 15(18):5829-39. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19737962) Bortezomib in the management Res. 2009 Sep 08; 1:107-17. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/21188129) Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple 27(27):4585-90. View Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood. 2009 Sep 24; 114(13):2699-708. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19652203) Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood. 2009 Oct 08; 114(15):3276-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19587378) Antimyeloma activity rapamycin Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. Single-agent bortezomib in previously untreated myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. a c-Myc/hypoxia-inducible in Cancer 2009 cytotoxicity myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15; 15(12):4028-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19509164) Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple RhoA cell-derived factor-1-induced cell adhesion and chemotaxis canonical nuclear View Blood. 2009 Jul 09; 114(2):371-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19417213) Clinical challenges associated [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19452315) benefit of novel therapies in multiple myeloma. Oncology (Williston Park). [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19476274) MicroRNAs 15a and 16 regulate tumor proliferation in myeloma. Blood. 2009 Jun 25; 113(26):6669-80. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19401561) Emerging Blood. 2009 May 21; 113(21):5228-36. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19270264) Emerging therapies Mar; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19231786) Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res. 2009 tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009 Apr 30; 113(18):4309-18. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19196658) The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009 Mar 26; 113(13):3040-9. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19164601) Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009 Apr 30; 113(18):4341-51. Insulin-like growth factor-1- and Prev. 2009 standard for translational cancer research. Clin cells in vitro and in Jan; 8(1):26-35. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19139110) in the biology, prognosis, and therapy of Waldenstr\u00f6m macroglobulinemia. Blood. 2009 Apr 30; 113(18):4391-402. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19074725) The current landscape of Dec; 32 Suppl 1:S1-24. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18954677) Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood. 2009 Feb 12; 113(7):1513-21. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/19018094) Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol. 143(4):511-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18986387) Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res. In vivo anti-myeloma activity and modulation of gene profile induced by valproic acid, a histone deacetylase angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood. 2009 Jan 22; 113(4):846-55. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18948577) Targeting the UPS as therapy myeloma. 2008 Oct 21; 9 of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant. 2008 Oct; 14(10):1118-1124. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18804041) Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood. 2008 Dec 15; 112(13):5095-102. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18824601) Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple Br J Haematol. 2008 Nov; 143(4):537-40. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18783399) Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma dyscrasias. Biologics. 2008 initial treatment of multiple myeloma. N Engl J Med. 2008 Aug [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18713945) changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18715819) Characterisation of and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. Oct; 143(2):222-9. of herpes events among bortezomib-treated patients in the phase III APEX study. J 2008 Oct 10; effect of telomerase Res. 2008 Aug 01; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18676772) Moving toward individualized cancer therapies. Cancer Res. 2008 Aug 01; 14(15):4682-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18676734) The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18452080) growth and survival of human multiple myeloma cells. Int J Oncol. 2008 Jul; 33(1):153-9. View Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008 Jul 01; 68(13):5216-25. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18593922) Bortezomib in Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity. Expert Opin Drug Metab efficacious multiple of patients with myeloma in the era of novel agents. J Clin Oncol. 2008 Jun 01; 26(16):2761-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18427148) Risks of cancer among a cohort of 23,935 men and women with osteoporosis. Int J Cancer. 2008 Apr 15; 122(8):1879-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18074348) Clinical, radiographic, and biochemical characterization multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. Apr 15; 14(8):2387-95. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18413829) Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br Haematol. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18334673) Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2008 May 01; 111(9):4752-63. trial of oral vorinostat (suberoylanilide hydroxamic SAHA) in look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2008 Mar 05; 100(5):373. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18314478) Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. 2008 Feb 01; 14(3):865-74. View Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest. 2008 Feb; 118(2):491-504. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18219387) A review of lenalidomide in combination with dexamethasone for the treatment of multiple class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S 105(4):1285-90. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18202175) Targeting [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17996588) From the bench to the bedside: emerging new treatments in multiple myeloma. Best Haematol. 2007 Dec; 20(4):797-816. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18070720) role the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1007-34, vii-viii. studies of View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17898564) relevant end points and new drug approvals for myeloma. Leukemia. 2008 Feb; 22(2):231-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17972944) Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res. 2007 Oct 15; 13(20):6162-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17947482) Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res. 2007 Oct 01; 13(19):5903-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17908986) The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008 Aug 15; 112(4):1329-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17906076) Inhibition of Akt induces of survivin and cytotoxicity in human multiple myeloma J 2007 Sep; 138(6):783-91. View Establishment of regulates survival homing in Blood. 2007 the interaction of multiple myeloma cells and osteoclasts. Blood. 2007 Nov 15; 110(10):3744-52. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17715391) Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 15; 110(10):3557-60. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17690257) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007 Aug; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17588472) Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem. 2007 Jul 01; 101(4):950-68. View 3-kinase Res. 2007 Jul 01; 13(13):3771-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17606706) Introducing the clinical connection. Res. 2007 Jul 01; 13(13):3761. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17606703) A strategic framework for novel drug development in multiple myeloma. Br J Haematol. 2007 Jul; 138(2):153-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17593022) Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol. 2007 Jun in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17602058) Novel in myeloma: the treatment paradigm. Oncology (Williston View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17575103) Does maintenance therapy American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Sep 01; 110(5):1656-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17510321) Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17475906) Targeting the beta-catenin/TCF treatment of multiple myeloma. Proc Natl Acad Sci U S A. 2007 May 104(18):7516-21. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17452641) Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007 View in: Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007 Apr 01; 109(7):2708-17. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17119115) Targeted of response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17418411) Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Expert Rev Anticancer DNA breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood. 2007 Jul 15; 110(2):709-18. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17384201) Emerging drugs 01; 6(5):538-42. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17351339) caspase-triggered c-Abl cleavage in human multiple 15; 67(4):1680-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17308109) High-throughput oncogene mutation profiling 39(3):347-51. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17293865) Protein in vivo activity macroglobulinemia. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17335683) The emerging role of novel therapies for the treatment of relapsed myeloma. J with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. in: Acad View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17213309) Inhibition of the TGF-beta signaling pathway in tumor cells. Recent Results Cancer Res. 2007; 172:77-97. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17607937) The treatment of View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/18024646) Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007 enhances 90 dexamethasone via of p38 mitogen-activated protein kinase/Hsp27 in multiple myeloma cell lines and inhibits paracrine tumour growth. Br in multiple myeloma. Proc Natl Acad Sci A. 2006 Dec 19; 103(51):19478-83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17164332) New frontiers in the treatment myeloma. ScientificWorldJournal. 2006 Dec 06; 6:1475-503. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17160337) Stem cell transplant for first relapse from the multiple myeloma research foundation. 12(22):6826-35. View Synopsis of novel therapeutics multiple myeloma. Clin Cancer Smac/DIABLO as for multiple (MM). Blood. 2007 Feb 01; 109(3):1220-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17032924) Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor Blood. 2007 Feb 15; 109(4):1669-77. View in Targets. inhibitor, blocks myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 01; 12(19):5887-94. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/17020997) Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Expert Proteasome Res. 2006 Aug 15; 66(16):7840-2. View in: A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15; 108(10):3458-64. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16840727) Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol. 2006 Jul; 134(2):145-56. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16846475) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006 Jul 01; 66(13):6675-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16818641) vivo R-etodolac dexamethasone in multiple in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16803565) Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response Haematologica. 2006 Jul; 91(7):929-34. View [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16818280) Specific killing of myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood. 2006 Oct 15; 108(8):2804-10. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16809610) Comparative selectivity proteasome inhibitors PS-341, and Cancer Res. 2006 Jun 15; 66(12):6379-86. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16778216) The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006 Jul; 42(11):1564-73. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16765041) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. resonance: a spatial-spectral holographic perspective. J Opt Soc Am A Opt Image Sci Vis. 2006 Jun; 108(10):3441-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16728695) CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell distinct of patients. Cancer Cell. 2006 Apr; 9(4):313-25. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16616336) Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Cancer. 2006 Mar 15; 106(6):1316-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16470606) FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol. 2006 Mar; 132(6):698-704. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16487170) Caveolin-1 as a potential new therapeutic target in multiple myeloma. Cancer Lett. 2006 Feb 20; 233(1):10-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16473666) of Investig Drugs. 2006 Feb; 15(2):171-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16433596) Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol. 2006 Feb; 132(4):385-97. View in: chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006 oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. mediates antiangiogenesis via direct and indirect effects on endothelial cells. Cancer Res. 2006 Jan 01; 66(1):184-91. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16409135) C: too much of a good thing? Clin Cancer Res. Jan 01; 12(1):3-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16397016) Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma. J Clin Oncol. 2005 Dec 15; 65(24):11712-20. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16357183) Intracellular protein degradation and its therapeutic implications. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8530-3. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16361533) FGFR3 as a of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 2005 Dec [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16506632) Safety of therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005 Nov 15; 104(10):2141-8. View A orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005 Nov; 8(5):407-19. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16286248) Antimyeloma 107(3):1092-100. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16234364) Lenalidomide and thalidomide: an resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005 Sep 15; 65(18):8350-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16166312) Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol. 2005 Sep 10; 23(26):6345-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16155018) Dysfunctional T regulatory cells in myeloma. Blood. 2006 Jan 01; 107(1):301-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16150935) Development of effective new treatments multiple myeloma. Clin Oncol. caspase-independent AIF/Endo G pathway. Oncogene. 2005 Sep 01; 24(38):5888-96. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15940263) Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res. 2005 Sep 01; 65(17):7896-901. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16140960) Emerging trends in the in multiple myeloma cells and overcomes drug resistance. Cancer Res. 2005 Aug 15; 65(16):7478-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16103102) Risk factors and kinetics associated with bortezomib for relapsed, refractory Blood. 2005 Dec 01; 106(12):3777-84. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16099887) Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005 Nov 01; 106(9):2977-81. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16020506) Perspectives for combination therapy to drug-resistant multiple Drug Resist anti-CD40 triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005 65(13):5898-906. View multiple myeloma. Proc Acad A. 2005 in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15937109) Combination and induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res. 2005 Jun 01; 11(11):4251-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15930364) Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol. 2005 Jun; 129(5):687-700. View in: 15; 106(4):1341-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15886318) Honokiol overcomes conventional drug resistance multiple myeloma by induction of caspase-dependent and for overcoming resistance using lysophosphatidic acid inhibitors. Oncogene. 2005 Apr 28; 24(19):3121-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15735676) Activity probe for in vivo profiling of the specificity of proteasome inhibitor 2005 Aug 01; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15827128) A clinically relevant SCID-hu in vivo model of human multiple myeloma. 15; View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15827343) options for older myeloma patients. From the Multiple Myeloma Research Foundation. Oncology (Williston 2005 Apr; 19(4):447-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15934516) Targeting for the multiple of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood. 2005 Jul 15; 106(2):706-12. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15802527) Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer. 2005 multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005 Jun 01; 105(11):4470-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15705788) Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005 May 15; 105(10):3945-50. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15692072) Proteasome inhibition in the Feb; 4(2):290-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15655370) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005 Jan 20; 23(3):630-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15659509) Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstr\u00f6m's macroglobulinemia. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/16250907) Novel biological therapies for multiple Pract Res Clin whereby immunomodulatory drugs activate natural killer cells: clinical application. Br 2005 is against View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15574786) Role of Nov 18; 23(54):8766-76. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15480425) inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res. 2004 Nov 15; 10(22):7540-6. View in: Focus on growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004 Oct 15; 64(20):7500-6. View pathophysiologic role of Feb 15; 105(4):1383-95. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15471951) Mcl-1 regulation and its role 2004 Oct; 3(10):1259-62. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15467463) Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood. 2005 Jan 01; 105(1):350-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15367426) A global expression-based analysis consequences of the t(4;14) translocation in myeloma. Clin Cancer Res. 2004 CC-5013 activity 2004 Dec 15; 104(13):4188-93. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15319277) Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function. Blood. 2005 Mar 01; 105(5):2235-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15292058) analogs Aug 15; 22(16):3212-4. View in: in 2004 Jul; 18(8):988-90. with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004 Jul; 79(7):875-82. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15244383) the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple 01; 64(13):4629-36. View in: Targeting mitochondria to bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) 104(8):2458-66. View VEGF Blood. 2004 Nov 01; 104(9):2886-92. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15217829) An update of novel therapeutic approaches for multiple myeloma. Curr Treat Br J Haematol. 2004 which SGN-40, antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15; 64(8):2846-52. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15087402) Advances in biology of multiple myeloma: clinical applications. Blood. 2004 Aug 01; 104(3):607-18. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15090448) TNFalpha induces rapid lymphocytes. Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells. J Biol Chem. 2004 May 14; 279(20):21658-65. receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. 5(3):221-30. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15050914) Telomerase inhibition and after telomestatin treatment in multiple myeloma. Clin Cancer in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/15224657) Strategies to improve the outcome of stem cell transplantation in multiple myeloma. Hematol J. 2004; by the triterpenoid and clinical implications. Proc Natl Acad Sci U S A. Blood. 2004 Apr 15; 103(8):3158-66. View (cardiotrophin-like cytokine) for human myeloma J Haematol. 2003 Dec; 123(5):869-78. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14632778) Broadening the spectrum of patient groups at risk for transfusion-associated GVHD: implications for universal irradiation of cellular blood components. Transfusion. 2003 Dec; 43(12):1652-4. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14641857) Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003 Dec 22(54):8797-801. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14647474) GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood. myeloma. Oncogene. 2003 Nov 22(52):8386-93. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14627979) Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood. 2004 Jan 15; 103(2):656-63. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14563636) Fluorescence imaging of multiple a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. Oct in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14583463) 2003 01; 63(19):6174-7. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14559800) The role telomerase RNA in human multiple Res. 2003 Oct 01; 63(19):6187-94. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14559802) Bortezomib: 103(5):1787-90. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/13679868) Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res. 2003 Sep 15; 63(18):5850-8. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14522909) Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004 Mar 01; 103(5):1799-806. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12969976) Telomerase inhibition and for the treatment of multiple myeloma and other cancers. Cancer Control. 2003 Sep-Oct; 10(5):361-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/14581890) Insights into the multistep transformation of MGUS to myeloma using microarray expression 2003 Dec 15; 102(13):4504-11. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12947006) Proteasome inhibitors disrupt response in myeloma cells. Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9946-51. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12902539) Novel therapeutic approaches 194:164-76. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12846814) 2003 Aug; 78(2):114-20. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12953804) Smac in multiple myeloma cells and confers dexamethasone resistance. Blood. 2003 Nov 01; 102(9):3379-86. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12855565) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl 26; is a potent deacetylase inhibitor with significant activity against multiple myeloma. 102(7):2615-22. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12816865) CD8+ CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res. 2003 in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop Macroglobulinemia. Semin in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12720146) MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM apoptosis in multiple myeloma (MM) cells. Biol Chem. 2003 May 16; 278(20):17593-6. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12665525) New agents and approaches Moving disease biology from the lab to the clinic. Cancer. 2003 Feb 01; 97(3 human cells. 101(10):4055-62. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12531799) translocation of reverse transcriptase protein. Cancer Res. 2003 Jan 01; 63(1):18-21. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12517770) The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant. 2003 Jan; 9(1):4-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12533739) Novel therapies for Jan; 120(1):10-7. View in: receptor in cells and modulates cell proliferation. Biochem Dec 13; of genes regulated (2ME2) in multiple myeloma cells using 01; insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. Biol Chem. 2003 Feb 21; 278(8):5794-801. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12482878) Moving disease biology from the the Oncol. 2002 Dec; 29(6 Suppl 17):17-20. View in: mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002 Dec; 2(12):927-37. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12459731) Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery. Cancer Ther. 2002 View in: myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood. cells to chemotherapeutic agents: therapeutic applications. Blood. 15; 101(6):2377-80. View CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002 Nov 01; 100(9):3063-7. View in: cells. Proc Acad S A. 2002 Oct 29; 99(22):14374-9. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12391322) Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors. Transfusion. 2002 Oct; 42(10):1279-84. View in: 2-Methoxyestradiol overcomes drug resistance in cells. Sep 15; 100(6):2187-94. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12200384) Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003 Jan 15; 101(2):703-5. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12393542) Novel PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 01; 62(17):5019-26. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12208756) Novel therapies for vivo and prolongs survival in a murine model. Cancer Res. 2002 Sep 01; 62(17):4996-5000. View in: Telomerase inhibitors 2002 Sep; 2(5):567-75. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12678724) American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple intracellular anti-apoptotic via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002 Aug 22; 21(37):5673-83. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12173037) Novel biologically based therapies inhibits growth of multiple myeloma cells in the bone marrow microenvironment. Mol Cancer herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma. Blood. 2002 Jul 15; 100(2):698-700. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12091368) beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Exp activity in a human multiple myeloma cell line. Cancer Res. 2002 Jul 01; 62(13):3876-82. [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12097303) Apoptotic in myeloma cells: 15; Immunologic effects of prophylactic infusion after allogeneic marrow transplantation for multiple Jun View in: of nuclear factor-kappaB multiple applications. Blood. 2002 Jun 01; 99(11):4079-86. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/12010810) What is the proper threshold for platelet transfusion in patients with chemotherapy-induced against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. Cancer Lett. 2002 Apr 25; 178(2):187-97. View and growth neoplasias Cancer Res. 2002 Apr 15; 62(8):2300-5. in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11956087) Immunization of dendritic and plasmacytoma cells is potentiated by interleukin Blood. 2002 Apr 01; 99(7):2512-7. View ligand-induced human multiple 99(6):2162-71. View in: of in: NF-kappa a therapeutic target in multiple myeloma. J Biol Chem. 2002 May 10; 277(19):16639-47. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11872748) Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide factor human multiple Feb View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11830495) Arsenic trioxide in multiple 2002 Jan-Feb; 8(1):12-25. in: 53:629-57. View patients migration multiple myeloma associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. Mar 277(10):7875-81. View in: [PubMed](http://www.ncbi.nlm.nih.gov/pubmed/11751905) Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell 24(3):263-271. View Multiple Myeloma: Insights "}